Bandhan Healthcare Fund - Regular Plan - Growth
₹10.1290
₹0.14 (-1.41%)
NAV as of 29 May 2026
Today's NAV — all variants
Regular · Growth
₹₹10.1290
₹0.14 (-1.41%)
29 May 2026
AMFI: 153974
Direct · Growth
₹₹10.2140
₹0.14 (-1.40%)
29 May 2026
AMFI: 153972
Regular · IDCW
₹₹10.1290
₹0.14 (-1.41%)
29 May 2026
AMFI: 153973
Direct · IDCW
₹₹10.2140
₹0.14 (-1.40%)
29 May 2026
AMFI: 153971
Returns (Lumpsum)
CAGR for periods ≥ 1 yearSIP Returns (XIRR)
₹1,000/month SIP, annualisedSIP since inception — what ₹100/month became
Real NAV backtest from day one
₹600
Invested
₹633
Value today
20.8%
XIRR (p.a.)
₹100/month SIP from fund inception · Current value as of today
Try SIP Calculator with this fund's history₹1,000 lumpsum at launch — value today
Invested on the fund's first NAV date
₹1,000
Invested
₹1,013
Value today
2.6%
CAGR (p.a.)
One-time investment at fund inception · Growth purely from NAV appreciation
Try Lumpsum Calculator₹6L corpus via 12-month STP from a liquid fund at inception
₹50K/month transferred from HDFC Liquid → this fund at launch
₹6,00,000
Invested
₹6,31,869
Value today
+4.0%
vs lumpsum
STP beat direct lumpsum by 4.0% — reduced timing risk paid off
Model your own STP with real NAVBeat the benchmark — ₹100/month SIP
Same SIP in this fund vs the benchmark index
This fund
₹633
Benchmark
₹596
+₹37 extra wealth vs the benchmark index
Backtest this SIP yourselfFund Details
Portfolio Holdings
Top 34 holdings · as of Mar 2026
| Security | % NAV |
|---|---|
Sun Pharmaceutical Industries Limited INE044A01036 | 9.65% |
Apollo Hospitals Enterprise Limited INE437A01024 | 8.97% |
Divi's Laboratories Limited INE361B01024 | 7.40% |
Max Healthcare Institute Limited INE027H01010 | 7.14% |
Dr. Reddy's Laboratories Limited INE089A01031 | 7.12% |
Cipla Limited INE059A01026 | 6.72% |
JB Chemicals & Pharmaceuticals Limited INE572A01036 | 4.91% |
Lupin Limited INE326A01037 | 3.81% |
Mankind Pharma Limited INE634S01028 | 3.31% |
Ajanta Pharma Limited INE031B01049 | 3.08% |
Glenmark Pharmaceuticals Limited INE935A01035 | 2.97% |
Aurobindo Pharma Limited INE406A01037 | 2.87% |
Dr. Lal Path Labs Limited INE600L01024 | 2.79% |
Global Health Limited INE474Q01031 | 2.46% |
Abbott India Limited INE358A01014 | 2.09% |
Rainbow Childrens Medicare Limited INE961O01016 | 1.92% |
Syngene International Limited INE398R01022 | 1.86% |
GlaxoSmithKline Pharmaceuticals Limited INE159A01016 | 1.84% |
Krishna Institute Of Medical Sciences Limited INE967H01025 | 1.82% |
Sai Life Sciences Limited INE570L01029 | 1.78% |
Pfizer Limited INE182A01018 | 1.73% |
Shilpa Medicare Limited INE790G01031 | 1.60% |
Aster DM Healthcare Limited INE914M01019 | 1.47% |
Star Health And Allied Insurance Company Limited INE575P01011 | 1.34% |
Sanofi India Limited INE058A01010 | 1.18% |
Jubilant Pharmova Limited INE700A01033 | 0.90% |
Medi Assist Healthcare Services Limited INE456Z01021 | 0.87% |
Healthcare Global Enterprises Limited INE075I01017 | 0.84% |
Concord Biotech Limited INE338H01029 | 0.75% |
Cohance Lifesciences Limited INE03QK01018 | 0.66% |
IPCA Laboratories Limited INE571A01038 | 0.59% |
Orchid Pharma Limited INE191A01027 | 0.42% |
Blue Jet Healthcare Ltd INE0KBH01020 | 0.36% |
Inventurus Knowledge Solutions Limited INE115Q01022 | 0.24% |
Performance Comparison
Interested in This Fund?
Our experts will help you decide if this fund fits your goals.
Compare with Similar Funds
Investment Objective
Bandhan Healthcare Fund - Regular Plan - Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
Bandhan Healthcare Fund - Regular Plan - Growth is a Sectoral / Thematic mutual fund offered by Bandhan Mutual Fund. The fund has been operational for over 0 years. It manages assets worth ₹287 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE HEALTHCARE INDEX TRI. The current expense ratio is 2.41%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations